Abstract
The predominance of insulin resistance, T2D linked pancreatic cancer has increased throughout the world. The insulin/IGF signaling pathway related to insulin resistance, T2D and pancreatic cancer has been described. In this context, we have demonstrated the role of miRNAs in cancer progression and control of miRNAs in insulin/IGF signaling pathway, and pancreatic cancer. In this paper, an overview was depicted about the role of following miRNAs in pancreatic development and insulin secretion (miR-375, miR-7, miR-124a2, miR-195, miR-126, miR-9, miR-96, miR-34a); insulingrowth factor-1 receptor expression (miR-7, miR-139, miR-145, miR-1); the diabetes-associated pancreatic cancer pathway genes such as IRS, PI3K, AKT/PKB (miR-128a, miR-19a, miR-21, miR-29 a/b/c); mTOR protein regulation (miR- 99, miR-21, miR-126, and miR-146a) etc. At last, we have also explained the role of miRNAs in diagnostic marker (miR- 200, miR-21, miR-103, miR-107, and miR-155) and as a therapeutic modulator (miR-34, miR-21, miR-221, and miR-101) in pancreatic cancer.
Keywords: miRNA, insulin/IGF-mTOR signaling pathway, insulin resistance, type-2 diabetes, pancreatic cancer.
Current Drug Targets
Title:miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’
Volume: 14 Issue: 10
Author(s): Chiranjib Chakraborty, George Priya Doss. C and Sanghamitra Bandyopadhyay
Affiliation:
Keywords: miRNA, insulin/IGF-mTOR signaling pathway, insulin resistance, type-2 diabetes, pancreatic cancer.
Abstract: The predominance of insulin resistance, T2D linked pancreatic cancer has increased throughout the world. The insulin/IGF signaling pathway related to insulin resistance, T2D and pancreatic cancer has been described. In this context, we have demonstrated the role of miRNAs in cancer progression and control of miRNAs in insulin/IGF signaling pathway, and pancreatic cancer. In this paper, an overview was depicted about the role of following miRNAs in pancreatic development and insulin secretion (miR-375, miR-7, miR-124a2, miR-195, miR-126, miR-9, miR-96, miR-34a); insulingrowth factor-1 receptor expression (miR-7, miR-139, miR-145, miR-1); the diabetes-associated pancreatic cancer pathway genes such as IRS, PI3K, AKT/PKB (miR-128a, miR-19a, miR-21, miR-29 a/b/c); mTOR protein regulation (miR- 99, miR-21, miR-126, and miR-146a) etc. At last, we have also explained the role of miRNAs in diagnostic marker (miR- 200, miR-21, miR-103, miR-107, and miR-155) and as a therapeutic modulator (miR-34, miR-21, miR-221, and miR-101) in pancreatic cancer.
Export Options
About this article
Cite this article as:
Chakraborty Chiranjib, Doss. C Priya George and Bandyopadhyay Sanghamitra, miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990182
DOI https://dx.doi.org/10.2174/13894501113149990182 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry Recent Patents on Live Bacteria and their Products as Potential Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery A Co-Module Regulated by Therapeutic Drugs in a Molecular Subnetwork of Alzheimer’s Disease Identified on the Basis of Traditional Chinese Medicine and SAMP8 Mice
Current Alzheimer Research Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity
Current Medicinal Chemistry Comparative Safety Assessment Study for Drospirenone Induced Gallbladder Diseases Using the Adverse Drug Reaction Database of USA, Europe, and Canada
Current Drug Safety Cannabinoids in Energy Balance and Prospectives in the Therapy of Obesity
Current Medicinal Chemistry - Central Nervous System Agents MicroRNA-dependent Regulation of Telomere Maintenance Mechanisms: A Field as Much Unexplored as Potentially Promising
Current Pharmaceutical Design Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Trichinella spiralis and Tumors: Cause, Coincidence or Treatment?
Anti-Cancer Agents in Medicinal Chemistry miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Immunological Mechanisms of Specific Allergen Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer
Current Clinical Pharmacology Matrix Metalloproteinase Inhibitors: A Review on Pharmacophore Mapping and (Q)Sars Results
Current Medicinal Chemistry Chemical Modifications of Ketoprofen (NSAID) in Search of Better Lead Compounds: A Review of Literature From 2004-2016
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets